These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 15453341)

  • 1. [Antiviral treatment of chronic hepatitis B with adefovir dipivoxil].
    Minami M; Okanoue T
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():336-9. PubMed ID: 15453341
    [No Abstract]   [Full Text] [Related]  

  • 2. First report of genotypic resistance to adefovir in chronic HBV in the Republic of Ireland.
    Laoi BN; Herra C; Norris S; Crowley B
    J Antimicrob Chemother; 2006 May; 57(5):1009-10. PubMed ID: 16524892
    [No Abstract]   [Full Text] [Related]  

  • 3. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year data released on Viread for chronic hepatitis B.
    AIDS Patient Care STDS; 2008 Nov; 22(11):921. PubMed ID: 19025487
    [No Abstract]   [Full Text] [Related]  

  • 5. [New antiviral agent. Hepatitis B therapy with slight resistance risk].
    MMW Fortschr Med; 2003 Dec; 145(51-52):40. PubMed ID: 14974332
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL;
    N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily.
    Hézode C; Chevaliez S; Bouvier-Alias M; Roudot-Thoraval F; Brillet R; Zafrani ES; Dhumeaux D; Pawlotsky JM
    J Hepatol; 2007 May; 46(5):791-6. PubMed ID: 17321635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adefovir dipivoxil: new preparation. A third-line option in chronic hepatitis B.
    Prescrire Int; 2004 Feb; 13(69):4-7. PubMed ID: 15055205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
    Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
    Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does pre-treatment with lamivudine prime for adefovir resistance of hepatitis B virus infection?
    Sirma H; Funk A; Gerlich W; Schildgen O
    J Antimicrob Chemother; 2007 Aug; 60(2):448-9. PubMed ID: 17561492
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL;
    Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical study of adding on adefovir dipivoxil to treat for lamivudine resistant patients with chronic hepatitis B].
    DING JG; SUN QF; FU RQ; WU YH; HONG L
    Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):387-8. PubMed ID: 19497209
    [No Abstract]   [Full Text] [Related]  

  • 13. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil.
    Delaney WE
    J Antimicrob Chemother; 2007 May; 59(5):827-32. PubMed ID: 17332007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
    Liu CJ; Kao JH; Chen PJ; Chen TC; Lin FY; Lai MY; Chen DS
    J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Non-standard discontinuation of adefovir dipivoxil causing acute exacerbation of hepatitis].
    Yang Z; Wu MS; Chen WL; Xiao L; Zhao LZ; Wei SJ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):711-3. PubMed ID: 19785968
    [No Abstract]   [Full Text] [Related]  

  • 16. [Recent advances in the treatment of the hepatitis HBV-related. Effectiveness and tolerability of adefovir dipivoxil].
    Palumbo E
    Recenti Prog Med; 2007 Apr; 98(4):237-8. PubMed ID: 17547362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A study on the treatment of chronic hepatitis B with YMDD mutation].
    Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B.
    Scotto G; Palumbo E; Fazio V; Tartaglia A; Saracino A; Angarano G
    New Microbiol; 2005 Jul; 28(3):193-7. PubMed ID: 16240690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis.
    Ohkawa K; Takehara T; Kato M; Kanada A; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
    J Med Virol; 2009 May; 81(5):798-806. PubMed ID: 19319954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.